BioSpace News Archive

Alvotech (NASDAQ: ALVO) and Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia® and Xgeva® (denosumab).

Protara Therapeutics, Inc. today announced that management will participate in a virtual fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit on Tuesday, May 28, 2024 at 3:00 pm ET.

Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the BIO International Convention, taking place June 3-6, 2024, in San Diego, CA.

AltruBio Inc., a clinical stage biotechnology company dedicated to the development of novel therapeutics for the treatment of immunological diseases with high unmet medical needs, announced an oversubscribed Series B financing of up to $225 million.

COUR Pharmaceuticals announced the appointment of Paul M. Peloso, MD, a seasoned drug developer with more than 20 years of experience advancing multiple therapeutic candidates through market approval, as chief medical officer.

PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, announced the introduction of GlueSEEKER™.

So-Young International Inc. announced that it will report its financial results for the first quarter ended March 31, 2024, before U.S. markets open on May 28, 2024.

Cali Biosciences Co., Ltd. announced publication of “CPL‑01, an investigational long‑acting ropivacaine, demonstrates safety and efficacy in open inguinal hernia repair” in the scientific journal Hernia.

Ironwood Pharmaceuticals, Inc. will present late-breaking data during the 2024 Digestive Disease Week® meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure.

Seed Health, a microbiome science company, launched VS-01™ Vaginal Synbiotic, the first vaginal synbiotic clinically validated to rapidly establish an optimal vaginal microbiome dominated by Lactobacillus crispatus, the vagina’s most protective bacteria.